Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood Advances Jg. 6; H. 12; S. 3606 - 3610
Hauptverfasser: Iacoboni, Gloria, Rejeski, Kai, Villacampa, Guillermo, van Doesum, Jaap A., Chiappella, Annalisa, Bonifazi, Francesca, Lopez-Corral, Lucia, van Aalderen, Michiel, Kwon, Mi, Martínez-Cibrian, Nuria, Bramanti, Stefania, Reguera-Ortega, Juan Luis, Camacho-Arteaga, Lina, Schmidt, Christian, Marín-Niebla, Ana, Kersten, Marie José, Martin Garcia-Sancho, Alejandro, Zinzani, Pier Luigi, Corradini, Paolo, van Meerten, Tom, Subklewe, Marion, Barba, Pere
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States Elsevier Inc 28.06.2022
American Society of Hematology
Schlagworte:
ISSN:2473-9529, 2473-9537, 2473-9537
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Author Bonifazi, Francesca
Villacampa, Guillermo
Lopez-Corral, Lucia
Bramanti, Stefania
Kersten, Marie José
Chiappella, Annalisa
Iacoboni, Gloria
Rejeski, Kai
Subklewe, Marion
Martin Garcia-Sancho, Alejandro
van Doesum, Jaap A.
Schmidt, Christian
Corradini, Paolo
Kwon, Mi
Zinzani, Pier Luigi
Camacho-Arteaga, Lina
van Meerten, Tom
Marín-Niebla, Ana
Reguera-Ortega, Juan Luis
van Aalderen, Michiel
Martínez-Cibrian, Nuria
Barba, Pere
Author_xml – sequence: 1
  givenname: Gloria
  orcidid: 0000-0003-0805-9288
  surname: Iacoboni
  fullname: Iacoboni, Gloria
  email: giacoboni@vhio.net
  organization: Department of Hematology, Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
– sequence: 2
  givenname: Kai
  surname: Rejeski
  fullname: Rejeski, Kai
  organization: Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
– sequence: 3
  givenname: Guillermo
  orcidid: 0000-0003-4868-6585
  surname: Villacampa
  fullname: Villacampa, Guillermo
  organization: Oncology Data Science, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
– sequence: 4
  givenname: Jaap A.
  orcidid: 0000-0003-0214-3219
  surname: van Doesum
  fullname: van Doesum, Jaap A.
  organization: Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
– sequence: 5
  givenname: Annalisa
  orcidid: 0000-0002-2977-0098
  surname: Chiappella
  fullname: Chiappella, Annalisa
  organization: Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milano, Milano, Italy
– sequence: 6
  givenname: Francesca
  surname: Bonifazi
  fullname: Bonifazi, Francesca
  organization: IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli”, Bologna, Italy
– sequence: 7
  givenname: Lucia
  orcidid: 0000-0003-1908-5596
  surname: Lopez-Corral
  fullname: Lopez-Corral, Lucia
  organization: Hematology Department, Hospital Clínico Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain
– sequence: 8
  givenname: Michiel
  surname: van Aalderen
  fullname: van Aalderen, Michiel
  organization: Department of Hematology, Amsterdam University Medical Centers, Cancer Center Amsterdam, LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam, The Netherlands
– sequence: 9
  givenname: Mi
  surname: Kwon
  fullname: Kwon, Mi
  organization: Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
– sequence: 10
  givenname: Nuria
  surname: Martínez-Cibrian
  fullname: Martínez-Cibrian, Nuria
  organization: Department of Hematology, Hospital Clinic, Barcelona, Spain
– sequence: 11
  givenname: Stefania
  surname: Bramanti
  fullname: Bramanti, Stefania
  organization: Istituto Clinico Humanitas IRCCS, Rozzano, Italy
– sequence: 12
  givenname: Juan Luis
  surname: Reguera-Ortega
  fullname: Reguera-Ortega, Juan Luis
  organization: Department of Hematology, University Hospital Virgen del Rocio, Sevilla, Spain
– sequence: 13
  givenname: Lina
  orcidid: 0000-0001-9609-0394
  surname: Camacho-Arteaga
  fullname: Camacho-Arteaga, Lina
  organization: Clinical Pharmacology Department, Vall d'Hebron University Hospital, Barcelona, Spain
– sequence: 14
  givenname: Christian
  surname: Schmidt
  fullname: Schmidt, Christian
  organization: Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
– sequence: 15
  givenname: Ana
  surname: Marín-Niebla
  fullname: Marín-Niebla, Ana
  organization: Department of Hematology, Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
– sequence: 16
  givenname: Marie José
  surname: Kersten
  fullname: Kersten, Marie José
  organization: Department of Hematology, Amsterdam University Medical Centers, Cancer Center Amsterdam, LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam, The Netherlands
– sequence: 17
  givenname: Alejandro
  orcidid: 0000-0001-6330-1028
  surname: Martin Garcia-Sancho
  fullname: Martin Garcia-Sancho, Alejandro
  organization: Hematology Department, Hospital Clínico Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain
– sequence: 18
  givenname: Pier Luigi
  orcidid: 0000-0002-2112-2651
  surname: Zinzani
  fullname: Zinzani, Pier Luigi
  organization: IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli”, Bologna, Italy
– sequence: 19
  givenname: Paolo
  surname: Corradini
  fullname: Corradini, Paolo
  organization: Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milano, Milano, Italy
– sequence: 20
  givenname: Tom
  surname: van Meerten
  fullname: van Meerten, Tom
  organization: Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
– sequence: 21
  givenname: Marion
  orcidid: 0000-0003-3905-0251
  surname: Subklewe
  fullname: Subklewe, Marion
  organization: Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
– sequence: 22
  givenname: Pere
  surname: Barba
  fullname: Barba, Pere
  organization: Department of Hematology, Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
BackLink https://cir.nii.ac.jp/crid/1872553967893867264$$DView record in CiNii
https://www.ncbi.nlm.nih.gov/pubmed/35271707$$D View this record in MEDLINE/PubMed
BookMark eNqNkUtv1TAQhSNURB_0LyAvWLBJ8SO2kw2CVhSQKiEhWFt-TKjBiW9t58L99zi6LYiu7sZjyd-cM55z2hzNcYamQQRfENLT1ybE6LTb6tlCvqCYEozFQOmT5oR2krUDZ_Lo750Ox815zj8wxkQKxgf6rDlmnEoisTxp7r6ADu2vmIJDsPUOqiiKIzIJfi9Wm6K_wwxILyUGWCwENMaEyi2gkkCXCeay4gmC3mRwqD4mGJO2JaYdmvRcAqDaFlDYTZvbOOnnzdNRhwzn9_Ws-Xb9_uvVx_bm84dPV-9uWssJLi3n4wCYmIESa0Ytbc87zDg3DgYpaDdSITnUSggfwQiqeW-wcdwNnbE9sLPm1V53k-LdArmoyed1Ej1DXLKigvWSMiZ4RV_co4uZwKlN8pNOO_Wwpgq82QM2xZzrB5X1RRcf55K0D4pgtUaj_otG_YumCvSPBB48Dmh9uW-dva-260nq4JyzQch-YL2QVHQVu9xjUHe69ZBUtn5N0_kEtigX_SFebx-J2FAdrQ4_YXeYxB-h89Ev
CitedBy_id crossref_primary_10_1158_2326_6066_CIR_22_0487
crossref_primary_10_1002_ajh_27056
crossref_primary_10_1182_bloodadvances_2023010364
crossref_primary_10_1111_bjh_18378
crossref_primary_10_1111_bjh_18697
crossref_primary_10_1002_hem3_87
crossref_primary_10_1182_bloodadvances_2021004535
crossref_primary_10_3389_fonc_2024_1407001
crossref_primary_10_1111_imj_16561
crossref_primary_10_1080_10428194_2024_2369653
crossref_primary_10_3389_fmed_2025_1553966
crossref_primary_10_1002_hon_3200
crossref_primary_10_1080_10428194_2023_2212098
crossref_primary_10_3390_cancers17132239
crossref_primary_10_1002_hon_70074
crossref_primary_10_1111_bjh_19617
crossref_primary_10_1016_j_csbj_2022_06_015
crossref_primary_10_3389_fimmu_2024_1519671
crossref_primary_10_3389_fonc_2024_1394057
crossref_primary_10_1186_s40164_024_00490_x
crossref_primary_10_1002_jha2_655
crossref_primary_10_1111_bjh_19131
crossref_primary_10_3389_fimmu_2024_1435127
crossref_primary_10_1080_10428194_2023_2220456
crossref_primary_10_1016_j_ejca_2024_115145
crossref_primary_10_1080_10428194_2024_2338851
crossref_primary_10_1016_j_hoc_2023_07_002
crossref_primary_10_1038_s41571_024_00903_0
crossref_primary_10_1111_bjh_19961
crossref_primary_10_1001_jamanetworkopen_2024_61683
crossref_primary_10_1016_j_clml_2024_02_010
crossref_primary_10_1111_imj_16544
crossref_primary_10_3390_ijms24065688
crossref_primary_10_1097_HS9_0000000000000907
crossref_primary_10_3389_fonc_2022_925818
crossref_primary_10_1016_j_phrs_2024_107158
crossref_primary_10_1182_blood_2023022353
crossref_primary_10_1016_j_jcyt_2024_07_015
crossref_primary_10_1016_S2352_3026_22_00355_6
crossref_primary_10_1080_14737159_2024_2399152
crossref_primary_10_1080_21645515_2024_2378543
crossref_primary_10_1136_jitc_2024_009349
crossref_primary_10_1182_blood_2023020578
crossref_primary_10_1080_13543784_2025_2472410
crossref_primary_10_1080_10428194_2024_2320833
crossref_primary_10_1016_j_critrevonc_2023_104085
crossref_primary_10_1177_20406207221142133
crossref_primary_10_3389_fphar_2023_1200808
crossref_primary_10_3390_cancers15174253
crossref_primary_10_1007_s11899_023_00687_7
crossref_primary_10_1038_s41591_024_03084_6
crossref_primary_10_1080_10428194_2023_2227748
crossref_primary_10_3390_biomedicines10081960
Cites_doi 10.1056/NEJMoa1914347
10.1002/cam4.3881
10.1002/ajh.26233
10.1016/j.bbmt.2018.12.758
10.1200/JCO.2013.54.8800
10.1200/JCO.19.02104
10.1182/bloodadvances.2020003092
10.1200/JCO.19.02103
ContentType Journal Article
Contributor Vall d'Hebron Barcelona Hospital Campus
[Iacoboni G, Marín-Niebla A, Barba P] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Rejeski K] Department of Medicine III, University Hospital, LMU Munich, Munich, Germany. [Villacampa G] Oncology Data Science, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain. The Institute of Cancer Research, London, United Kingdom. [van Doesum JA] Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. [Chiappella A] Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milano, Milano, Italy. [Bonifazi F] IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Sera
Contributor_xml – sequence: 1
  fullname: Institut Català de la Salut
– sequence: 2
  fullname: [Iacoboni G, Marín-Niebla A, Barba P] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Rejeski K] Department of Medicine III, University Hospital, LMU Munich, Munich, Germany. [Villacampa G] Oncology Data Science, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain. The Institute of Cancer Research, London, United Kingdom. [van Doesum JA] Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. [Chiappella A] Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milano, Milano, Italy. [Bonifazi F] IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seragnoli”, Bologna, Italy. [Camacho-Arteaga L] Servei de Farmacologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca de Farmacologia Clínica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Farmacologia, Terapèutica i Toxicologia, Universitat Autònoma de Barcelona, Bellaterra, Spain
– sequence: 3
  fullname: Vall d'Hebron Barcelona Hospital Campus
Copyright 2022 The American Society of Hematology
Copyright_xml – notice: 2022 The American Society of Hematology
DBID 6I.
AAFTH
RYH
AAYXX
CITATION
NPM
7X8
DOI 10.1182/bloodadvances.2021006922
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CiNii Complete
CrossRef
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
EISSN 2473-9537
EndPage 3610
ExternalDocumentID 35271707
10_1182_bloodadvances_2021006922
S2473952922001616
Genre Journal Article
GroupedDBID .1-
.FO
0R~
53G
AALRI
AAXUO
AAYWO
ACVFH
ADCNI
ADVLN
AEUPX
AFPUW
AFRHN
AIGII
AITUG
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
EBS
FDB
GROUPED_DOAJ
H13
HYE
OK1
ROL
RPM
THE
W2D
Z5R
6I.
AAFTH
AFCTW
RYH
AAYXX
CITATION
NPM
7X8
ID FETCH-LOGICAL-c510t-55f9e01b921cbfa7c8540355bde97624f2675e24f115feb62a58b0bd5d94bc8e3
ISICitedReferencesCount 65
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000836434600006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2473-9529
2473-9537
IngestDate Fri Sep 05 06:37:40 EDT 2025
Thu Jan 02 22:55:03 EST 2025
Sat Nov 29 03:31:39 EST 2025
Tue Nov 18 21:42:12 EST 2025
Mon Nov 10 09:05:48 EST 2025
Thu Jul 20 20:10:09 EDT 2023
Tue Aug 26 16:31:28 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 12
Language English
License This is an open access article under the CC BY-NC-ND license.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c510t-55f9e01b921cbfa7c8540355bde97624f2675e24f115feb62a58b0bd5d94bc8e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-2977-0098
0000-0003-0805-9288
0000-0001-6330-1028
0000-0003-0214-3219
0000-0003-3905-0251
0000-0003-1908-5596
0000-0003-4868-6585
0000-0001-9609-0394
0000-0002-2112-2651
0000-0002-4117-7991
OpenAccessLink http://dx.doi.org/10.1182/bloodadvances.2021006922
PMID 35271707
PQID 2638723365
PQPubID 23479
PageCount 5
ParticipantIDs proquest_miscellaneous_2638723365
pubmed_primary_35271707
crossref_citationtrail_10_1182_bloodadvances_2021006922
crossref_primary_10_1182_bloodadvances_2021006922
nii_cinii_1872553967893867264
elsevier_sciencedirect_doi_10_1182_bloodadvances_2021006922
elsevier_clinicalkey_doi_10_1182_bloodadvances_2021006922
PublicationCentury 2000
PublicationDate 2022-06-28
PublicationDateYYYYMMDD 2022-06-28
PublicationDate_xml – month: 06
  year: 2022
  text: 2022-06-28
  day: 28
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Blood Advances
PublicationTitleAlternate Blood Adv
PublicationYear 2022
Publisher Elsevier Inc
American Society of Hematology
Publisher_xml – name: Elsevier Inc
– name: American Society of Hematology
References Wang, Munoz, Goy (bib1) 2020; 382
Iacoboni, Villacampa, Martinez-Cibrian, GETH, GELTAMO Spanish Groups (bib8) 2021; 10
Khurana, Dalland, Young, Inwards, Paludo (bib2) 2021; 96
Pasquini, Hu, Curran (bib7) 2020; 4
Lee, Santomasso, Locke (bib3) 2019; 25
Cheson, Fisher, Barrington, United Kingdom National Cancer Research Institute (bib4) 2014; 32
Jacobson, Hunter, Redd (bib6) 2020; 38
Nastoupil, Jain, Feng (bib5) 2020; 38
Cheson (2022062015231013200_B4) 2014; 32
Jacobson (2022062015231013200_B6) 2020; 38
Nastoupil (2022062015231013200_B5) 2020; 38
Lee (2022062015231013200_B3) 2019; 25
Pasquini (2022062015231013200_B7) 2020; 4
Khurana (2022062015231013200_B2) 2021; 96
Iacoboni (2022062015231013200_B8) 2021; 10
Wang (2022062015231013200_B1) 2020; 382
References_xml – volume: 25
  start-page: 625
  year: 2019
  end-page: 638
  ident: bib3
  article-title: ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells
  publication-title: Biol Blood Marrow Transplant.
– volume: 382
  start-page: 1331
  year: 2020
  end-page: 1342
  ident: bib1
  article-title: KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma
  publication-title: N Engl J Med.
– volume: 38
  start-page: 3095
  year: 2020
  end-page: 3106
  ident: bib6
  article-title: Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity
  publication-title: J Clin Oncol.
– volume: 32
  start-page: 3059
  year: 2014
  end-page: 3068
  ident: bib4
  article-title: Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification
  publication-title: J Clin Oncol.
– volume: 4
  start-page: 5414
  year: 2020
  end-page: 5424
  ident: bib7
  article-title: Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma [published correction appears in
  publication-title: Blood Adv.
– volume: 96
  start-page: E298
  year: 2021
  end-page: E301
  ident: bib2
  article-title: Brexucabtagene autoleucel therapy induces complete remission in a primary refractory blastoid mantle cell lymphoma with neurolymphomatosis
  publication-title: Am J Hematol.
– volume: 10
  start-page: 3214
  year: 2021
  end-page: 3223
  ident: bib8
  article-title: Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma
  publication-title: Cancer Med.
– volume: 38
  start-page: 3119
  year: 2020
  end-page: 3128
  ident: bib5
  article-title: Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium
  publication-title: J Clin Oncol.
– volume: 382
  start-page: 1331
  issue: 14
  year: 2020
  ident: 2022062015231013200_B1
  article-title: KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMoa1914347
– volume: 10
  start-page: 3214
  issue: 10
  year: 2021
  ident: 2022062015231013200_B8
  article-title: Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma
  publication-title: Cancer Med.
  doi: 10.1002/cam4.3881
– volume: 96
  start-page: E298
  issue: 8
  year: 2021
  ident: 2022062015231013200_B2
  article-title: Brexucabtagene autoleucel therapy induces complete remission in a primary refractory blastoid mantle cell lymphoma with neurolymphomatosis
  publication-title: Am J Hematol.
  doi: 10.1002/ajh.26233
– volume: 25
  start-page: 625
  issue: 4
  year: 2019
  ident: 2022062015231013200_B3
  article-title: ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells
  publication-title: Biol Blood Marrow Transplant.
  doi: 10.1016/j.bbmt.2018.12.758
– volume: 32
  start-page: 3059
  issue: 27
  year: 2014
  ident: 2022062015231013200_B4
  article-title: Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.2013.54.8800
– volume: 38
  start-page: 3119
  issue: 27
  year: 2020
  ident: 2022062015231013200_B5
  article-title: Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.19.02104
– volume: 4
  start-page: 5414
  issue: 21
  year: 2020
  ident: 2022062015231013200_B7
  article-title: Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma
  publication-title: Blood Adv.
  doi: 10.1182/bloodadvances.2020003092
– volume: 38
  start-page: 3095
  issue: 27
  year: 2020
  ident: 2022062015231013200_B6
  article-title: Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.19.02103
SSID ssj0001763592
ssib053239758
Score 2.458551
SourceID proquest
pubmed
crossref
nii
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 3606
SubjectTerms Adult
Antineoplastic Agents
Humans
Immunotherapy, Adoptive
Investigative Techniques::Immunologic Techniques::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT]
Limfomes - Tractament
Lymphoma, Mantle-Cell
neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células del manto [ENFERMEDADES]
Neoplasm Recurrence, Local
Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, Mantle-Cell [DISEASES]
Other subheadings::Other subheadings::/drug therapy [Other subheadings]
Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]
Pyrimidines
Real-world, brexucabtagene autoleucel, relapsed refractory, mantle cell lymphoma
Receptors, Chimeric Antigen
Research Letter
Teràpia cel·lular
técnicas de investigación::técnicas inmunológicas::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS]
Title Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma
URI https://www.clinicalkey.com/#!/content/1-s2.0-S2473952922001616
https://dx.doi.org/10.1182/bloodadvances.2021006922
https://cir.nii.ac.jp/crid/1872553967893867264
https://www.ncbi.nlm.nih.gov/pubmed/35271707
https://www.proquest.com/docview/2638723365
Volume 6
WOSCitedRecordID wos000836434600006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2473-9537
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0001763592
  issn: 2473-9529
  databaseCode: DOA
  dateStart: 20160101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2473-9537
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssib053239758
  issn: 2473-9529
  databaseCode: M~E
  dateStart: 20160101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Jj9MwFLbagQMXBGIrMCMjcasyJE68RJxGMIh1hGAY9RbZjiMVhaR0GXUu_Bx-J89OnLSgSkWIi1slsbO8L37fc96C0NOQ6CSRzARccxkkuQoDKXIVhIYnikoSKVc64eI9PzsTk0n6cTD46WNhLkteVWK9Tmf_VdSwDYRtQ2f_QtzdoLAB_oPQoQWxQ7uX4D8B9QtcItSxaUuGWkYIpu96paVawgQCxFKulnVpQK5l52jY-5zD4TbGZbYANgo7QYnOXVmeK-vsCucY2-X-cXkFSKjbed1_F7Z-8N6xoKPrb2DaVbUrHmXdOxrP5uY7j_lq2srZ7-TUb72wpZC0TQXpeqxcvOK32u-2IVcva7NoSjS_lXI2PjneXL4AyzdkPhzcran5uJott0-S8DhIabsW0s7TbBOOZGPSjVnINhR4zBpH2T-Vg7DJZl1AgH8Ox8TavCFLm-Do31Jvf7bXYS-DEEeN2RBdI5ymYsN0d2t5Nqufq7_dXbh3GhPk2a4T7mJCw2o63W3vON5zfgvdbA0WfNIA7TYamOoO-t6DDHuQ4brA2yDDPcgwgAwDyHAHMnu4BxmGnT3IcAMybEGGPcjuoi-vTs9fvA7a4h2Bhml-GVBapCaMVEoirQrJtQDbAMityg0wYJIUBExVA79gkhRGMSKpUKHKaZ4mSgsT30MHVV2ZBwiD2pG0ULpQSZjohCppIh0WDMbgmuVshLh_kJluM9vbAitl5ixcQbItEWS9CEYo6nrOmuwue_RJvawyH70M-jYDlO3R93nXt2W4DXPds_chQANu0baR4ITSOAWymcaCcTBsRuiJB00GSsJKSVamXsEYoGU5iWNGR-h-g6bufsEC4xEP-cN_uK9H6Eb_bj9GB8v5yhyi6_pyOV3Mj9CQT8SRe2Wg_fDj9BfNZfRb
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Real-world+evidence+of+brexucabtagene+autoleucel+for+the+treatment+of+relapsed+or+refractory+mantle+cell+lymphoma&rft.jtitle=Blood+advances&rft.au=Iacoboni%2C+Gloria&rft.au=Rejeski%2C+Kai&rft.au=Villacampa%2C+Guillermo&rft.au=van+Doesum%2C+Jaap+A.&rft.date=2022-06-28&rft.pub=Elsevier+Inc&rft.issn=2473-9529&rft.volume=6&rft.issue=12&rft.spage=3606&rft.epage=3610&rft_id=info:doi/10.1182%2Fbloodadvances.2021006922&rft.externalDocID=S2473952922001616
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2473-9529&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2473-9529&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2473-9529&client=summon